The financing round was led by new investor Flat Capital, with continued participation from existing investors Industrifonden and Navigare Ventures.

“This financing gives us the resources to expand globally as demand grows for our Proxiome Kit and our data analysis and visualization software,” says Pixelgen CEO and co-Founder Simon Fredriksson. “We’re proud to have Flat Capital join us and to have the continued confidence of Navigare and Industrifonden. Their support will help accelerate our commercial reach, grow our team and product portfolio, and bring molecular cell architecture to more researchers and new applications.”

El Tarzi and Ramon Felciano

Alongside the financing, Pixelgen is adding Flat Capital CEO Rickard El Tarzi and life sciences industry veteran Ramon Felciano, to its board of directors.

El Tarzi brings extensive experience in investments, strategic development and board leadership from his time in private equity and industry. He joins the board in his capacity as CEO of Flat Capital. Previous experience includes serving as Chief Strategy & Product Officer at Olink Proteomics, now part of Thermo Fisher Scientifc, where he helped shape the company’s strategic direction through its initial public offering and eventual sale.

Ramon Felciano, PhD, is a life sciences technology entrepreneur working at the intersection of data, technology, and life sciences. He founded Ingenuity Systems, a pioneer in AI-driven genome interpretation and precision medicine, acquired by QIAGEN in 2013 for $105 million. At QIAGEN he served as chief technology officer and vice president of data strategy, founding QIAGEN Digital Insights, the company’s industry-leading molecular data and AI software business unit. On the board, Felciano will work with Pixelgen’s leadership to build digital capabilities (software and data) that help translate the company’s technical differentiation – the molecular cell architecture platform – into company-level competitive advantage.

“Rickard and Ramon bring highly complementary experience to Pixelgen at an important stage in our growth,” Fredriksson says. “Rickard understands what it takes to scale and commercialize life sciences research platforms globally, while Ramon has built AI and data businesses with products that have been adopted by biotech R&D, a key sector for us moving forward.”